In cardiovascular disease, ADP is a key regulator of platelet activity and inhibition of the purinergic receptor P2Y12 has thus emerged as an important therapeutic strategy to reduce recurrent cardiovascular events [72, 75]. This evidence concerns the gene P2RY12 and cardiovascular disorder.